Physician profile
Eric L Balthaser
NPI 1184770281
$418.09
in general payments reported to CMS, 2019-2025
12 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $83.46 · 2024: $177 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $103.02 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $89.86 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $37.47 | 2023-2025 | Miebo, Xiidra, Infuse |
| Johnson & Johnson Vision Care, INC. | $34.64 | 2023 | Acuvue |
| Oyster Point Pharma, INC. | $34.30 | 2023-2024 | Tyrvaya |
| Dompe US, INC. | $24.35 | 2024 | Oxervate |
| Amgen INC. | $17.78 | 2025 | Tepezza |
| Alcon Vision LLC | $17.50 | 2023 | Total30 |
| Biotissue Holdings INC. | $16.00 | 2024 | |
| Harrow Eye, LLC | $15.92 | 2024 | Vevye |
| Ani Pharmaceuticals, INC. | $13.66 | 2025 | Iluvien |
| Sun Pharmaceutical Industries INC. | $13.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Balthaser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.